Figure 4
From: Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
Treatment-related adverse events and immune-related adverse events between different immune checkpoint inhibitors: (A) any grade; (B) grade 1–2; (C) grade 3–5.
